Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
A coating for an expandable portion of a catheter comprising a hydrophobic matrix and a dispersed phase is disclosed. The dispersed phase comprises a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a first biodegradable or bioerodable polymer. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.
1. A catheter comprising:
an expandable portion on an elongated body; and
a coating over an outer surface of the expandable portion, wherein the coating comprises:
a hydrophobic matrix, wherein the hydrophobic matrix comprises a cholesterol and a phospholipid, wherein the phospholipid comprises an acyl chain phospholipid with an acyl chain length of about 20 to about 34;
a dispersed phase comprising a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a first biodegradable or bioerodable polymer; and
wherein the hydrophobic matrix is configured to adhere to a luminal surface when the expandable portion is expanded, and transfer at least a portion of the plurality of micro-reservoirs to the luminal surface.
2. The catheter of claim 1 , further comprising a release layer between the expandable portion and the coating, wherein the release layer is configured to release the coating from the expandable portion.
3. The catheter of claim 2 , wherein the release layer comprises DSPE-mPEG350 or DSPE-mPEG500.
4. The catheter of claim 2 , wherein the release layer has a surface concentration of about 0.1 μg/mm 2 to about 5 μg/mm 2 .
5. The catheter of claim 1 , further comprising a protective coating over the coating.
6. The catheter of claim 5 , wherein the protective coating comprises a hydrophilic polymer, a carbohydrate, an amphiphilic polymer, a glycosoaminoglycan, or a crystallized sugar.
7. The catheter of claim 5 , wherein the protective coating has a surface concentration of about 0.1 μg/mm 2 to about 5 μg/mm 2 .
8. The catheter of claim 1 , wherein the weight ratio of cholesterol to phospholipid is in the range of about 1:2 to about 3:1.
9. The catheter of claim 1 , wherein the phospholipid with an acyl chain length of about 20 to about 34 is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol.
10. The catheter of claim 1 , wherein the acyl chain phospholipid is selected from the group consisting of dieicosenoyl phosphatidylcholine (1,2-dieicosenoyl-sn-glycero-3-phosphocholine, C20:1 PC), diarachidonoyl phosphatidylcholine (1,2-diarachidoyl-sn-glycero-3-phosphocholine, C20:0 PC), dierucoyl phosphatidylcholine (1,2-dierucoyl-sn-glycero-3-phosphocholine, C22:1 PC), didocosahexaenoyl phosphatidylcholine (1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, C22:6 PC), heneicosenoyl phosphatidylcholine (1,2-heneicosenoyl-sn-glycero-3-phosphocholine, C21:1 PC), and dinervonyl phosphatidylcholine (1,2-dinervonoyl-sn-glycero-3-phosphocholine, C24:1 PC).
11. The catheter of claim 1 , wherein the hydrophobic matrix comprises a cholesterol and a cationic phospholipid.
12. The catheter of claim 11 , wherein the cationic phospholipid is phosphatidylethanolamine, dioleoylphosphatidylethanolamine (DOPE), or an amine derivative of phosphatidylcholine, each with an acyl chain length of about 20 to about 34.
13. The catheter of claim 1 , wherein the hydrophobic matrix comprises DC-Cholesterol and a phospholipid.
14. The catheter of claim 1 , wherein the plurality of micro-reservoirs is about 10% to about 75% by weight of the coating.
15. The catheter of claim 1 , wherein the plurality of micro-reservoirs has an average diameter of about 1.5 microns to about 8 microns.
16. The catheter of claim 15 , wherein the plurality of micro-reservoirs has an active agent release kinetics with a half-life of at least 14 days.
17. The catheter of claim 1 , wherein the first biodegradable or bioerodable polymer is selected from the group consisting of polylactic acid, polyglycolic acid and their copolymers, polydioxanone, polycaprolactone, polyphosphazine, collagen, gelatin, chitosan, glycosoaminoglycans, and combinations thereof.
18. The catheter of claim 1 , wherein the first active agent is selected from the group consisting of paclitaxel, sirolimus, paclitaxel derivative, sirolimus derivative, paclitaxel analogues, sirolimus analogues, inhibitory RNA, inhibitory DNA, steroids, and complement inhibitors.
19. The catheter of claim 1 , wherein the first active agent is about 10% to about 50% by weight of the plurality of micro-reservoirs.
20. The catheter of claim 1 , wherein the first active agent is intermixed with or dispersed in the first biodegradable or bioerodable polymer.
21. The catheter of claim 1 , wherein the hydrophobic matrix further comprises a PEG-lipid.
22. The catheter of claim 21 , wherein the PEG-lipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-350 (DSPE-mPEG350), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-methoxy(polyethyleneglycol)-350 (DPPE-mPEG350), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-350 (DOPE-mPEG350), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-550 (DSPE-mPEG550), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-550 (DPPE-mPEG550), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-500 (DOPE-mPEG550).
23. The catheter of claim 21 , wherein the PEG-lipid is about 1% to about 30% by weight of the hydrophobic matrix.
24. The catheter of claim 21 , wherein the PEG-lipid is about 2% to about 25% by weight of the hydrophobic matrix.
25. The catheter of claim 1 , further comprising one or more additives independently selected from penetrating enhancers and stabilizers.
26. The catheter of claim 1 , wherein the coating has a surface concentration of about 1 μg/mm 2 to about 10 μg/mm 2 .
27. The catheter of claim 1 , wherein the coating further comprises a second active agent outside of the plurality of micro-reservoirs.
28. The catheter of claim 27 , wherein the second active agent is selected from the group consisting of paclitaxel, sirolimus, paclitaxel derivative, sirolimus derivative, paclitaxel analogues, sirolimus analogues, inhibitory RNA, inhibitory DNA, steroids, and complement inhibitors.
29. The catheter of claim 1 , wherein the coating is homogenous.